- Report
- January 2026
- 186 Pages
Global
From €3450EUR$3,939USD£2,994GBP
- Report
- January 2026
- 198 Pages
Global
From €3450EUR$3,939USD£2,994GBP
- Report
- October 2025
- 250 Pages
Global
From €3932EUR$4,490USD£3,413GBP
- Drug Pipelines
- April 2025
- 280 Pages
Global
From €2627EUR$3,000USD£2,280GBP
- Report
- July 2025
- 175 Pages
Global
From €3932EUR$4,490USD£3,413GBP
- Clinical Trials
- April 2025
- 60 Pages
Global
From €1752EUR$2,000USD£1,520GBP
- Report
- February 2026
Global
From €450EUR$550USD£404GBP
- Report
- May 2024
- 200 Pages
Global
From €3635EUR$4,150USD£3,155GBP
- Report
- January 2024
- 182 Pages
Global
€4375EUR$4,995USD£3,797GBP
- Report
- February 2026
Global
From €450EUR$550USD£404GBP
From €104EUR$119USD£90GBP
- Book
- June 2020
- 198 Pages

Chemokines are a family of small proteins that are involved in the regulation of cell movement and communication. They are important in the immune system, as they are involved in the recruitment of immune cells to sites of infection or inflammation. In the biotechnology market, chemokines are used in the development of therapeutics for a variety of diseases, including cancer, autoimmune diseases, and infectious diseases.
Chemokines are also used in the development of diagnostics, such as biomarkers for disease progression and prognosis. Additionally, chemokines are used in the development of vaccines, as they can be used to target specific immune cells to the site of infection.
Companies in the chemokines market include AbbVie, Amgen, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Merck, Novartis, Pfizer, and Roche. Show Less Read more